Cardiovascular Outcomes in Medicare Patients Taking CGRP Monoclonal Antibodies

Among Medicare recipients with migraine, the incidence of stroke or myocardial infarction did not differ between those starting CGRP monoclonal antibodies and those starting onabotulinumtoxinA.

Both calcitonin gene-related peptide (CGRP) and its receptor are highly expressed in coronary arteries. Antagonism of either CGRP or its receptor theoretically increases vascular risk. To examine this potential association, these researchers conducted a retrospective cohort study based on Medicare claims data for adult patients who initiated either CGRP monoclonal antibody (mAb) therapy (5153 patients) or onabotulinumtoxinA (OBA) therapy (4000 patients). Patients with myocardial infarction, stroke, cluster headache, or malignancy within the year before the study were excluded.

The median follow-up period was 4.3 and 4.4 months for the CGRP mAb and OBA groups, respectively. The median age was 57.8 years in the CGRP mAb group and 61.9 years in…

Reviewing Authors

Usman Ashraf, MBBS, Mmed

Peter J. Goadsby, MD, PhD, DSc

Disclosures

Consultant/Advisory BoardAeon Biopharma; Allergan/Abbvie; CoolTech LLC; Dr Reddys; Eli Lilly and Company, Epalex; Lundbeck; Novartis; Pfizer; Praxis; Sanofi; Teva Pharmaceuticals and Tremeau; Gerson Lehrman Group; Guidepoint; Massachusetts Medical Society; Vector Metric; UptoDate

RoyaltiesOxford University Press; Wolters Kluwer

Grant/Research SupportCelgene

Leadership Positions in Professional SocietiesAmerican Headache Society (Immediate Past President)

OtherPatent on magnetic stimulation for headache assigned to eNeura without fee